Cost-effectiveness of teduglutide in adult patients with short bowel syndrome - a European socioeconomic perspective

CONCLUSION: Teduglutide in treating SBS-IF patients meets the traditional cost-effectiveness criteria from a European societal perspective. Nevertheless, the varying levels of teduglutide efficacy leave a degree of uncertainty to the calculations.PMID:38431119 | DOI:10.1016/j.ajcnut.2024.02.031

Source: The American Journal of Clinical Nutrition - March 2, 2024 Category: Nutrition Authors: Evelyn Walter Christopher Dawoud Elisabeth H ütterer Anton Stift Felix Harpain Source Type: research